6-K - BGM - Equibles

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TORULE 13a-16 OR 15d-16UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of February 2023

QILIAN INTERNATIONAL HOLDING GROUP LTD

(Exact name of registrant as specified in its charter)

Jiuquan Economic and Technological DevelopmentZone

Jiuquan City, Gansu Province, 735000+86-028-64775180

(Address of Principal Executive Office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F x	Form 40-F ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨

On February 23, 2023, Qilian International Holding Group Ltd (the “Company”) received a letter (the “Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”) stating that since the Company has not yet filed its Form 20-F for the year ended September 30, 2023 (the “Filing”), it no longer complies with Nasdaq Listing Rules (the “Rules”) for continued listing under Listing Rule 5250(c)(1).

Under Nasdaq’s Rules the Company now has 60 calendar days to submit a plan to regain compliance and if Nasdaq accepts the Company’s plan, Nasdaq can grant the Company an exception of up to 180 calendar days from the Filing’s due date, or until August 14, 2023, to regain compliance.

The Company shall email its plan to Nasdaq no later than April 16, 2023. If Nasdaq does not accept the Company’s plan, the Company will have the opportunity to appeal that decision to a Hearings Panel.

The Letter has no effect on the listing of the Company’s shares at this time and the Company’s ordinary shares will continue to trade on The Nasdaq Global Market under the symbol “QLI.”

Exhibit

Exhibit Number	Exhibit
99.1	Press Release dated February 23, 2023

| 1 |

| --- |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Qilian International Holding Group Ltd
Date: February 23, 2023	By:	/s/ Zhanchang Xin
	Name:	Zhanchang Xin
	Title:	Chief Executive Officer

| 2 |

| --- |

Exhibit 99.1

Qilian Received Notification of Deficiency fromNasdaq Related to not timely Filing of Annual Report Form 20-F

JIUQUAN, China, February 23, 2023 /PRNewswire/– Qilian International Holding Group Ltd (NASDAQ: QLI) (“Qilian” or the “Company”), a China-based pharmaceutical and chemical products manufacturer, today announced it has received a notice of non-compliance from Nasdaq Stock Market LLC (“Nasdaq”) on February 16, 2023 stating that, as a result of not having timely filed its annual report on Form 20-F for the year ended September 30, 2022, Qilian is not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires timely filing of periodic financial reports with the Securities and Exchange Commission. This notice has no immediate effect on the listing or trading of Qilian’s ordinary shares on Nasdaq.

Under Nasdaq’s listing rules, the Company has 60 calendar days to submit a plan to regain compliance. If the plan is accepted by Nasdaq, the Company can be granted up to 180 calendar days from the Company’s Form 20-F’s filing due date, or until August 14, 2023, to regain compliance.

About Qilian International Holding Group Ltd

Qilian International Holding Group Ltd, headquartered in Gansu, China, is a pharmaceutical and chemical products manufacturer in China. It focuses on the development, manufacture, marketing and sale of licorice products, oxytetracycline products, traditional Chinese medicine derivatives product, heparin product, sausage casings, and fertilizers. The Company’s products are sold in more than 20 provinces in China. For more information, visit the Company’s website at http://ir.qlsyy.net.

Forward-Looking Statements

This press release contains forward-lookingstatements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerningplans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other thanstatements of historical facts. When the Company uses words such as “may, “will, “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate” or similar expressionsthat do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guaranteesof future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company’s expectationsdiscussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, thefollowing: the Company’s goals and strategies; the Company’s future business development; products demand and acceptance; changesin technology; economic conditions; reputation and brand; the impact of competition and pricing; government regulations; fluctuationsin general economic and business conditions in China; the COVID-19 outbreak and its impact on our operations and assumptions underlyingor related to any of the foregoing and other risks contained in reports filed by the Company with the Securities and Exchange Commission.For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this pressrelease. Additional factors are discussed in the Company’s filings with the U.S. Securities and Exchange Commission, which are availablefor review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-lookingstatements to reflect events or circumstances that arise after the date hereof.